BTTX Insider Trading

Insider Ownership Percentage: 59.40%
Insider Buying (Last 12 Months): $616,553.27
Insider Selling (Last 12 Months): $0.00

Better Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Better Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Better Therapeutics Share Price & Price History

Current Price: $1.76
Price Change: Price Increase of +0.06 (3.53%)
As of 09/30/2022 01:00 AM ET

This chart shows the closing price history over time for BTTX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

Better Therapeutics Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/15/2022Frank KarbeInsiderBuy50,000$2.09$104,500.0050,000View SEC Filing Icon  
9/12/2022Mark HeinenInsiderBuy23,868$1.94$46,303.9243,868View SEC Filing Icon  
6/24/2022Mark HeinenInsiderBuy2,281$1.75$3,991.752,281View SEC Filing Icon  
6/13/2022Geoffrey M ParkerDirectorBuy25,000$1.45$36,250.0040,000View SEC Filing Icon  
6/10/2022Mark HeinenInsiderBuy5,000$1.56$7,800.0020,000View SEC Filing Icon  
3/31/2022Kevin J. AppelbaumCEOBuy2,500$1.97$4,925.006,250View SEC Filing Icon  
3/31/2022Mark HeinenInsiderBuy5,000$1.98$9,900.0015,000View SEC Filing Icon  
3/29/2022Andrew J. ArmaninoDirectorBuy40,000$2.14$85,600.00View SEC Filing Icon  
12/21/2021Risa J. Lavizzo-MoureyDirectorBuy10,000$4.60$46,000.00View SEC Filing Icon  
12/20/2021Kevin J. AppelbaumCEOBuy1,000$4.60$4,600.00View SEC Filing Icon  
12/15/2021Kevin J. AppelbaumCEOBuy750$4.71$3,532.50View SEC Filing Icon  
12/15/2021Mark HeinenInsiderBuy2,333$4.70$10,965.10View SEC Filing Icon  
12/13/2021Andrew J. ArmaninoDirectorBuy21,000$5.48$115,080.00View SEC Filing Icon  
12/13/2021Mark HeinenInsiderBuy500$5.45$2,725.00View SEC Filing Icon  
12/10/2021Kevin J. AppelbaumCEOBuy1,000$5.98$5,980.00View SEC Filing Icon  
12/3/2021Elder GrangerDirectorBuy1,000$6.66$6,660.00View SEC Filing Icon  
12/2/2021Kevin J. AppelbaumCEOBuy500$6.84$3,420.00View SEC Filing Icon  
11/29/2021Andrew J. ArmaninoDirectorBuy17,000$6.96$118,320.00View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for Better Therapeutics (NASDAQ:BTTX)

7.48% of Better Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at BTTX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Better Therapeutics Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/15/2022State Street Corp45,200$71K0.0%N/A0.191%Search for SEC Filing on Google Icon
5/17/2022Alyeska Investment Group L.P.236,931$0.47M0.0%-31.2%1.004%Search for SEC Filing on Google Icon
5/17/2022Farallon Capital Management LLC1,147,400$2.27M0.0%-15.0%4.860%Search for SEC Filing on Google Icon
5/13/2022Vanguard Group Inc.284,395$0.56M0.0%+39.6%1.205%Search for SEC Filing on Google Icon
5/10/2022Sectoral Asset Management Inc.878,531$1.74M0.3%-9.8%3.721%Search for SEC Filing on Google Icon
5/4/2022Victory Capital Management Inc.272,720$0.54M0.0%N/A1.155%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Better Therapeutics logo
Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.
Read More on Better Therapeutics

Today's Range

Now: $1.76
Low: $1.68
High: $1.79

50 Day Range

MA: $1.86
Low: $1.53
High: $2.77

52 Week Range

Now: $1.76
Low: $0.91
High: $29.40


42,325 shs

Average Volume

133,744 shs

Market Capitalization

$41.78 million

P/E Ratio


Dividend Yield




Who are the company insiders with the largest holdings of Better Therapeutics?

Better Therapeutics' top insider shareholders include:
  1. Frank Karbe (Insider)
  2. Mark Heinen (Insider)
  3. Geoffrey M Parker (Director)
  4. Kevin J Appelbaum (CEO)
  5. Andrew J Armanino (Director)
  6. Elder Granger (Director)
  7. Risa J Lavizzo-Mourey (Director)
Learn More about top insider investors at Better Therapeutics.